Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ANAVEX2-73 open-label extension in early Alzheimer's disease
NL-OMON50754Phase 3Recruiting
- Sponsor
- Anavex Life Sciences Corp.
- Start
- Mar 2022
- Modality
- Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of blarcamesine in Alzheimer's disease (AD) and Dementia, sponsored by Anavex Life Sciences Corp. Primary endpoint: Safety and tolerability of ANAVEX2-73. Started Mar 2022; status: recruiting.
02
Drugs
blarcamesine
03
Conditions
Alzheimer's disease (AD)Dementia
Beyond the preview
Go deeper on NL-OMON50754.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON50754.